MediciNova (MNOV) Insider Hideki Nagao Buys 44,500 Shares

Hideki Nagao recently bought 44,500 shares of MediciNova, Inc. (NasdaqGM: MNOV) on June 23, 2026. The shares were acquired without a specified price, reflecting a strategic move in his investment portfolio.

Other Institutional Activity in MediciNova

Institutional investors have shown varied interest in MediciNova. For instance, Essex Woodlands Management, Inc. held steady with 1,105,941 shares valued at about $1.52 million. BlackRock, Inc. added 984 shares, ending with 705,954 shares worth approximately $967,157, marking a slight 0.1% increase. Vanguard Capital Management LLC opened a new position with 611,039 shares valued at $837,123. Geode Capital Management, LLC increased its holdings by 14,260 shares, totaling 543,843 shares with a value of $745,254, representing a 2.7% increase.

MediciNova, Inc. Stock Down 60.5%

Shares of MediciNova (NasdaqGM: MNOV) traded near $1.31 on Friday. The company has a market capitalization of approximately $64.5 million. MediciNova's forward P/E ratio is not meaningful as it is not currently profitable. The stock has experienced a 52-week low of $1.17 and a high of $1.96, with a 50-day moving average of $1.36 and a 200-day moving average of $1.41. The current ratio stands at 9.09, indicating strong liquidity, and the debt-to-equity ratio is 0.42.

Insider Buying and Selling at MediciNova, Inc.

Alongside Hideki Nagao, other insiders also bought shares on June 23, 2026. Carolyn Beaver and Nicole Lemerond each purchased 44,500 shares. Earlier in the year, on January 16, 2026, Chief Medical Officer Kazuko Matsuda and President and CEO Yuichi Iwaki each acquired 350,000 and 450,000 shares, respectively.

Analysts Set New Price Targets

Analysts maintain a positive outlook on MediciNova. On May 4, 2026, D. Boral Capital maintained its 'buy' rating with a $9.00 price target. Maxim Group reinstated a 'buy' rating with a $6.00 target on March 23, 2026, while HC Wainwright & Co. initiated coverage with a 'buy' rating and a $10.00 target on March 16, 2026. The consensus target price stands at $9.00, based on three analyst opinions.

About MediciNova, Inc.

MediciNova, Inc. is a biopharmaceutical company based in La Jolla, California, focusing on developing treatments for serious diseases with unmet medical needs. The company is advancing MN-166 (ibudilast) for neurological disorders like multiple sclerosis and glioblastoma, and MN-001 (tipelukast) for fibrotic diseases. Led by CEO Dr. Yuichi Iwaki, MediciNova operates in the biotechnology sector with a small team of six employees.

Bottom Line

MediciNova continues to attract attention from insiders and institutional investors alike. While the company is not currently profitable, its ongoing research in unmet medical needs keeps it on analysts' radar with positive ratings. Investors should remember that insider transactions and institutional activities are based on past data and may not reflect current positions.